Biosion, Inc. - Nov 18, 2024 Form 3 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: 10%+ Owner
Signature: /s/ Biosion, Inc. by: MINGJIU CHEN, CEO
Stock symbol: ACRS
Transactions as of: Nov 18, 2024
Transactions value $: $0
Form type: 3
Date filed: 11/25/2024, 11:03 AM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ACRS	Warrants (right to buy)							Nov 18, 2024	Common Stock	11.3M	$0.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On November 18, 2024, Aclaris Therapeutics, Inc. ("Aclaris") and Biosion, Inc. ("Biosion") entered into a Common Stock Purchase Warrant (the "Warrant"). Pursuant to the Warrant, Biosion, its designee or its permitted assigns, upon meeting certain terms and conditions of the Warrant, is entitled to exercise the warrant for up to 11,281,985 shares of Aclaris Common Stock. The Warrant was exercisable as of November, 18 2024 and may be exercised until the date on which the Warrant is exercised in full.

Content

On November 18, 2024, Aclaris Therapeutics, Inc. ("Aclaris") and Biosion, Inc. ("Biosion") entered into a Common Stock Purchase Warrant (the "Warrant"). Pursuant to the Warrant, Biosion, its designee or its permitted assigns, upon meeting certain terms and conditions of the Warrant, is entitled to exercise the warrant for up to 11,281,985 shares of Aclaris Common Stock. The Warrant was exercisable as of November, 18 2024 and may be exercised until the date on which the Warrant is exercised in full.